X

Marginal Zone Lymphoma

Marginal Zone Lymphoma

Copanlisib-Rituximab Combination May Improve Survival

The majority of patients (60%) had FL, 20.7% had MZL, 10.9% had small lymphocytic lymphoma, and 8.3% had lymphoplasmacytic lymphoma/Waldenström macroglobulinemia.

Cancer Therapy Advisor
06/11/2021
Emergency Splenectomy in a Patient with Splenic Marginal Zone Lymphoma, Acute Portal Vein Thrombosis, and Chronic Viral Hepatitis B

Investigators present a case of emergency splenectomy in a patient owing to difficulties in the diagnosis of splenic marginal zone lymphoma, rapid onset of acute portal vein thrombosis, and...

06/09/2021
The Role of Axicabtagene Ciloleucel as a Treatment Option for Patients With Follicular/Marginal Zone Lymphoma

CAR T-cell therapy with axicabtagene ciloleucel continues to make its way in the treatment of B-cell lymphomas.

Therapeutic Advances in Hematology
05/29/2021

Treatments and Outcomes in Stage I Extranodal Marginal Zone Lymphoma in the United States

The present study assesses the SEER database aiming to examine management and survival of localized EMZL. 

Cancers
04/09/2021
Novel Agents and Regimens for Hematological Malignancies: Recent Updates From 2020 ASH Annual Meeting

This study summarizes the latest updates on novel agents and regimens for hematological malignancies from the 2020 ASH annual meeting.

Journal of Hematology & Oncology
04/21/2021
miR-15a/16-1 Deletion in Activated B Cells Promotes Plasma Cell and Mature B-Cell Neoplasms

Upon BCR antigen stimulation, follicular B cells undergo T-cell–dependent activation, whereas marginal zone and B1 B cells undergo mainly T-cell–independent activation.

Blood
04/08/2021
FDA Approves Umbralisib for Two Lymphomas

The FDA granted approval to umbralisib for the treatment of adults with R/R MZL who have received at least one prior anti-CD20-based regimen and for adults with R/R FL who have...

Medscape
02/08/2021
EBV-Positive Extra-Nodal Marginal Zone Lymphoma Associated With XMEN Disease Caused by a Novel Hemizygous Mutation in MAGT1

This literature examines the the first known case of an EBV+ EMZL associated with XMEN disease.

Frontiers in Oncology
03/18/2021
Detection of Rare Germline Variants in the Genomes of Patients with B-Cell Neoplasms

Study investigators analyze the genomes of patients with B-cell lymphoproliferative disorders for the discovery of genes enriched in rare pathogenic variants.

Cancers
03/16/2021
PI3K Inhibitors in Cancer: Clinical Implications and Adverse Effects

This review focuses on the current landscape of various PI3K inhibitors either as monotherapy or in combination therapies and the treatment outcomes involved in various phases of clinical trials in

International Journal of Molecular Sciences
03/27/2021
Biological Significance of NOTCH Signaling Strength

This literature reviews mechanisms establishing different NOTCH signaling strengths, developmental processes sensitive to NOTCH signaling strength perturbation...

Frontiers in Cell and Developmental Biology
03/26/2021
Preclinical Efficacy and Anti-Inflammatory Mechanisms of Action of the Bruton Tyrosine Kinase Inhibitor Rilzabrutinib for Immune-Mediated Disease

Rilzabrutinib oral BTK inhibitor has long residence time and low systemic exposure.

 

Journal of Immunology
03/05/2021
Peripheral Eosinophil Counts Predict Efficacy of Anti-CD19 CAR-T Cell Therapy Against B-Lineage Non-Hodgkin Lymphoma

The aim of this study is to identify blood cell populations associated with beneficial outcomes in B-NHL patients administered CAR-T cell immunotherapies.

03/04/2021
Ultrasound and Bioptic Investigation of Patients With Primary Sjögren’s Syndrome

Authors summarize the role of different imaging techniques and a bioptic approach in pSS patients, focusing mainly on the role of salivary gland ultrasonography and a US-guided core needle biopsy a

Journal of Clinical Medicine
03/11/2021
Current and Emerging Therapeutic Options for Hairy Cell Leukemia Variant

This review examines the diagnostic criteria and clinical characteristics of HCL-v and presents a comprehensive overview of current therapeutic options in HCL-v.

OncoTargets and Therapy
03/09/2021
Targeting Bruton Tyrosine Kinase Using Non-covalent Inhibitors in B Cell Malignancies

This review discusses the rationale for the use of non-covalent BTK inhibitors and the preclinical and clinical studies of non-covalent BTK inhibitors in B cell malignancies.

Journal of Hematology & Oncology
03/06/2021
Biophysical Analysis of Acute and Late Toxicity of Radiotherapy in Gastric Marginal Zone Lymphoma—Impact of Radiation Dose and Planning Target Volume

The study provides practicable data to calculate risks for neighbored organs at risk in modern radiation planning with currently lower radiation doses...

Cancers
03/19/2021
Non-Coding RNAs (miRNAs and lncRNAs) and Their Roles in Lymphogenesis in All Types of Lymphomas and Lymphoid Malignancies

The present review provides an up-to-date summary of the recent literature referring to all diagnosed ncRNAs that mediate the pathogenesis of all types of lymphomas and lymphoid malignancies.

Oncology Letters
03/18/2021
Primary Hepatic Extranodal Marginal Zone Lymphoma of Mucosa-Associated Lymphoid Tissue in a Patient with Chronic Hepatitis B Virus Infection

Presented here is a rare case of primary hepatic extranodal marginal zone lymphoma of MALT with underlying hepatitis B infection and present useful diagnostic findings of various imaging modalities

Medicina
03/18/2021
Dermatological Considerations in the Diagnosis and Treatment of Marginal Zone Lymphomas

The aim of this review is to describe the clinical and histological findings for the diagnosis of PC-MZL, and the state of art for the management of the patient.

Clinical, Cosmetic and Investigational Dermatology
03/08/2021
Efficacy and Safety of Copanlisib in Patients With Relapsed or Refractory Marginal Zone Lymphoma

Enhanced efficacy outcomes can result from prolonged duration of copanlisib therapy in patients with relapsed/refractory MZL.

Blood Advances
02/05/2021
Active Surveillance of Primary Extranodal Marginal Zone Lymphoma of Bronchus-Associated Lymphoid Tissue

This retrospective study shows that BALT lymphoma can often be managed expectantly and not require therapy for many years.

Blood Advances
01/15/2021
Durable Ibrutinib Responses in Relapsed/Refractory Marginal Zone Lymphoma: Long-Term Follow-Up and Biomarker Analysis

Study investigators find that with extended follow-up, ibrutinib demonstrates durable clinical benefit in patients with relapsed/refractory MZL.

Blood Advances
11/23/2020

source list reference

rgb(171, 222, 222)
#7d60d9
#2694a4
#32a887
200, 66, 245
#85eb24
rgb(195, 2, 230)
#352625
#4d4537
rgb(209, 15, 15)
rgb(115, 43, 196)
rgb(9, 151, 227)
#d2093c
#8e3f1c
rgb(242, 0, 137)
#76b6c3
rgb(48, 38, 189)
rgb(231, 165, 240)
rgb(230, 21, 49)
#bfcfc8
#c61417
rgb(156, 242, 7)
#67e25b
#efef71
#03cffc
rgb(224, 4, 129)
#42fc9a
rgb(80, 147, 199)
#cc529a
#c59445
#c8cc0c
#bf6be3
#e8085a
#97d1a0
#74e391
#eb6342
#b61f77
#a153ac
rgb(5, 235, 235)
#e7f6e3
#6fc969
#9a8c2c
#a9c507
rgb(235, 190, 9)
#2b9ab3
#e61923
rgb(209, 227, 11)
#990677
#4a7bab
200, 66, 245
#89f67c
#49a21d
#2c990a
#d7da81
#f5ce42
rgb(217, 7, 192)
#575662
#a60538
rgb(2, 230, 230)
#49cde9
#c20fce
rgb(80,199,199)
#d95d39
#eb5834